UPMC Hillman Cancer Center is exploring everything radiation treatment can treat, and the success has been life-changing for people.
Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AML HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc.
Morning Overview on MSN
Study links beta cell cholecystokinin to obesity-driven pancreatic cancer
Researchers have identified a specific hormone produced by pancreatic beta cells as a direct driver of obesity-linked ...
Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature ...
Money Talks News on MSN
New pancreatic cancer treatment tracks tumors through your entire body
Scientists created an immunotherapy that tracks pancreatic cancer even after it spreads. The breakthrough treatment works in lab studies, though long-term safety in humans remains unknown.
Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AML HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc.
Last month, the United States Food and Drug Administration (FDA) approved a new wearable device for treating pancreatic cancer. This device, called Optune | Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results